Mechanisms of disease: proatherogenic HDL--an evolving field (Q36587579)

15 August 2017

1 reference

title

Mechanisms of disease: proatherogenic HDL--an evolving field (English)

1 reference

15 August 2017

Mohamad Navab

1

1 reference

15 August 2017

Gattadahalli M Anantharamaiah

2

1 reference

15 August 2017

Srinivasa T Reddy

3

1 reference

15 August 2017

Brian J Van Lenten

4

1 reference

15 August 2017

Benjamin J Ansell

5

1 reference

15 August 2017

Alan M Fogelman

6

1 reference

15 August 2017

1 September 2006

1 reference

Nature Clinical Practice Endocrinology and Metabolism

15 August 2017

1 reference

15 August 2017

2

1 reference

15 August 2017

9

1 reference

15 August 2017

504-511

1 reference

HDL and the inflammatory response induced by LDL-derived oxidized phospholipids

15 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

Abnormal reverse cholesterol transport in controlled type II diabetic patients. Studies on fasting and postprandial LpA-I particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may Be due to the abnormal composition of HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

The double jeopardy of HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

On evolutionary biology, inflammation, infection, and the causes of atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

Oxidized LDL-induced injury and apoptosis in atherosclerosis. Potential roles for oxysterols

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

A role for oxidized phospholipids in atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

Pathophysiology of coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

Antiinflammatory properties of HDL.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

Molecular mechanism of reverse cholesterol transport: reaction of pre-beta-migrating high-density lipoprotein with plasma lecithin/cholesterol acyltransferase

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

Tyrosine modification is not required for myeloperoxidase-induced loss of apolipoprotein A-I functional activities

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

When good cholesterol goes bad.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

High-density lipoprotein and the dynamics of atherosclerotic lesions

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

Drugs in development: targeting high-density lipoprotein metabolism and reverse cholesterol transport

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

Apolipoprotein A-I mimetic peptides

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

An apolipoprotein A-I mimetic works best in the presence of apolipoprotein A-I

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

Oral small peptides render HDL antiinflammatory in mice and monkeys and reduce atherosclerosis in ApoE null mice.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

Apolipoprotein A-I mimetic peptides: potential role in atherosclerosis management

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0245

7 January 2021

Identifiers

DOI

10.1038/NCPENDMET0245

1 reference

15 August 2017

1 reference